TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today published eight brief quotes from medical researchers, clinicians and policy experts on November 1, 2026. The roundup covered an American Diabetes Association report, clinical trial findings, board-exam software problems, reproductive technology, insurance policy and medication interactions; it did not provide full details or resolve the questions raised.
MedPage Today published eight comments from researchers, clinicians and policy experts in its November 1, 2026, “What We Heard This Week” roundup, spanning an American Diabetes Association report, several study findings, a medical board-exam software problem and health-policy disputes. The excerpts signal issues drawing attention across medicine, but the roundup is a brief selection of quotations rather than a full account of the underlying reports or evidence.
The most pointed comment concerned the American Diabetes Association’s final report about five scientists ousted from this year’s annual meeting. Aaron Kelly, PhD, of the University of Minnesota, said: “They’re looking for scapegoats.” The excerpt does not describe the report’s conclusions, the circumstances of the scientists’ removal or the association’s response, so Kelly’s assessment should be read as his view rather than a verified finding about the report’s intent.
Two other excerpts highlighted clinical research. Hugh Gallagher, MBBS, PhD, of Epsom and St Helier University Hospitals NHS Trust in England, commented after a trial found that low-dose aspirin did not reduce major vascular events among adults with chronic kidney disease. Nathalie Gaspar, MD, PhD, of Gustave Roussy in France, described positive phase III results for an investigational osteosarcoma drug tested in adolescents and adults as “Something we have not seen for years.” The roundup gives no trial names, numerical results or details about regulatory status.
The remaining comments touched on professional testing, fertility technology and policy. Aaron Gans, MD, raised concern about a possible data-collection error after receiving an “indeterminate” internal medicine board-exam score amid widespread software glitches. Hemant Suryawanshi, PhD, discussed an AI-powered tool intended to detect extremely rare sperm in men with azoospermia. Other remarks addressed obstacles to reforming the No Surprises Act, possible interactions between GLP-1 drugs and lithium, and increases in hemoglobin and hematocrit associated with SGLT2 inhibitors.
Research and Care Questions in Focus
The roundup brings together developments with potential consequences for patients, clinicians and medical institutions, but the excerpts do not establish the size or practical effect of those consequences. The aspirin result, for example, concerns a specific trial population and outcome; it does not by itself settle every question about aspirin use in people with chronic kidney disease. Likewise, positive phase III results for an investigational cancer drug are a research milestone, not confirmation that the treatment is approved or available.
The comments on exam software and the diabetes-association report point to a different kind of concern: trust in institutional processes and data. If exam scoring or data collection has been affected by technical problems, affected professionals may need clear explanations and a reliable review process. The excerpts raise those questions but do not report a final technical finding or remedy.
For readers, the value of the roundup is breadth rather than a single decisive announcement. It flags topics that may merit closer attention, while the limited detail means that the quotations cannot substitute for the underlying studies, reports or policy analysis.
Popular right now
Shark Rotator Lift-Away Upright Vacuum with HEPA Filter (NV501)
TCL QM64L 85-Inch QD-Mini LED 4K Smart Fire TV
Vitamix Propel Series 750 Professional-Grade Blender, 4 Programs, Black
As an affiliate, we earn on qualifying purchases.
Eight Comments, Several Fields
“What We Heard This Week” is presented by MedPage Today as a collection of quotations heard by its reporters. The edition dated November 1, 2026, contains eight remarks from people affiliated with universities, hospitals, a cancer center, a fertility clinic and a policy institute. It ranges from clinical trials and medication questions to professional testing and federal health policy.
The excerpts refer to separate developments rather than one connected event. They do not provide links to the specific trial publications, the ADA report, the exam-system investigation or the policy proposals discussed. The framing is therefore best understood as a weekly news roundup, not a comprehensive assessment or an endorsement of every speaker’s interpretation.
““They’re looking for scapegoats.””
— Aaron Kelly, PhD, University of Minnesota
Underlying Evidence Still Missing
The roundup does not provide enough information to independently assess several of its most consequential claims. It does not identify the studies, sample sizes, outcome measures or effect estimates behind the aspirin, osteosarcoma and medication findings. It also does not state whether the investigational cancer drug has moved toward regulatory review or what clinical guidance, if any, follows from the reported drug-interaction concerns.
For the ADA report and board-exam glitches, the excerpts leave unresolved what the relevant organizations concluded, whether data were affected and what corrective actions may be planned. The comments are attributable, but the underlying explanations and responses are not included. The roundup also does not provide enough detail to evaluate the AI fertility tool’s performance or the proposed changes to the No Surprises Act.
Full Reports Will Add Detail
The next useful developments will be the full reports and primary sources behind the excerpts: the ADA’s findings and any response from the association, the clinical-trial publications and follow-up on the exam software problem. Those materials could clarify what was measured, how reliable the findings are and what action is being considered.
For now, the November 1 roundup records the speakers’ reactions and identifies topics under discussion. It does not announce a single resolution or provide a timetable for one. Readers seeking practical implications should look for the underlying study results, official statements and subsequent reporting as they become available.
Key Questions
What is “What We Heard This Week”?
It is MedPage Today’s roundup of quotations heard by its reporters. The November 1, 2026, edition included eight comments on medical research, clinical care, professional testing and policy.
What prompted the “scapegoats” comment?
Aaron Kelly, PhD, made the comment about the American Diabetes Association’s final report concerning five scientists ousted from this year’s annual meeting. The excerpt does not include the report’s conclusions or the ADA’s response.
What did the aspirin trial find?
According to the roundup, a trial found that low-dose aspirin did not reduce major vascular events among adults with chronic kidney disease. The excerpt supplies no further trial details, so it does not establish broader guidance for other patients or outcomes.
Did the roundup say the osteosarcoma drug is approved?
No. It reports positive phase III trial results for an investigational drug tested in adolescents and adults, but gives no information about regulatory approval or availability.
What remains unresolved about the board-exam software problem?
The excerpt says Aaron Gans received an “indeterminate” score amid widespread software glitches and quotes his concern about a possible data-collection error. It does not report a confirmed cause, the number of affected examinees or a final remedy.
Source: medpagetoday.com
